MedPath

A clinical trial to study the safety and effect of the siddha medicine kattu karunai chooranam in patients having haemorrhoids (Mulai Moolam)

Phase 2
Not yet recruiting
Conditions
First degree hemorrhoids,
Registration Number
CTRI/2020/08/027446
Lead Sponsor
Government Siddha Medical College
Brief Summary

This is Phase II Non randomised open clinical evaluation trial to study the safety and efficacy of siddha Medicine Kattu Karunai Chooranam for Mulai Moolam. The trial Drug is given 1 gram twice a day with cows butter milk for 48 days. Clinical trial conducted after condicting after preclinical toxicity study. The trial drug Kattu Karunai Chooranam mentioned in Agathiyar 2000 part 2. During the trial all the study related data will be recorded and documented. Ater complition of the trial all the data will be analysed statistically.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Patients with appropriate symptoms like Bleeding during defecation Constipation Pain in anal region Per rectal examination pile mass present.

Exclusion Criteria

Pregnant and lactating mothers Second degree haemorrhoids External haemorrhoids Fissure in ano Fistula Ca Rectum Rectal Prolapse Hb less than 8mg/dl.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Outcome is mainly assessed byreduction in clinical symptoms measured by reduction in pain, cessation of bleeding during defecation constipation48 days
Secondary Outcome Measures
NameTimeMethod
Secondary outcome is comparing the safety parameters before and after treatment48 days

Trial Locations

Locations (1)

Arignar anna government hospital of indian medicine

🇮🇳

Chennai, TAMIL NADU, India

Arignar anna government hospital of indian medicine
🇮🇳Chennai, TAMIL NADU, India
Dr priya s
Principal investigator
9566207386
priya.131093@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.